KR Harrap
Impact in
- Oncology top 10%
- Metal complexes synthesis and properties
- Drug Transport and Resistance Mechanisms
- Cancer Treatment and Pharmacology
- Pathology and Forensic Medicine top 10%
- Chemotherapy-induced organ toxicity mitigation
Papers in
- Oncology 11
- Metal complexes synthesis and properties 6
- Colorectal Cancer Treatments and Studies 3
- Cancer Treatment and Pharmacology 3
- Drug Transport and Resistance Mechanisms 3
- Co-authors
- Prakash Mistry (1 shared paper)G Abel (1 shared paper)LR Kelland (4 shared papers)AH Calvert (4 shared papers)DR Newell (1 shared paper)Mark J. McKeage (1 shared paper)Newell (5 shared papers)J Siracký (1 shared paper)
- Journals
- British Journal of Cancer (7 papers)British Journal of Clinical Pharmacology (1 paper)International Journal of Oncology (1 paper)Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) (1 paper)PubMed (7 papers)
- Partner nations
- United KingdomUnited States
In The Last Decade
KR Harrap
20 papers receiving 587 citations
Peers
Comparison fields: 5 of 75
- Oncology 355
- Pathology and Forensic Medicine 127
- Biochemistry 34
- Hematology 41
- Molecular Biology 252
Countries citing papers authored by KR Harrap
This map shows the geographic impact of KR Harrap's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by KR Harrap with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites KR Harrap more than expected).
Fields of papers citing papers by KR Harrap
This network shows the impact of papers produced by KR Harrap. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by KR Harrap. The network helps show where KR Harrap may publish in the future.
Co-authors
The 22 scholars most cited alongside KR Harrap, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1991 | 233 | |
| 2 | 1993 | 98 | |
| 3 | Some observations on the human pharmacology of methotrexate. | 1977 | 39 |
| 4 | 1993 | 38 | |
| 5 | 1983 | 36 | |
| 6 | 1987 | 34 | |
| 7 | Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717). | 1987 | 25 |
| 8 | Pharmacokinetics of the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) in the mouse. | 1986 | 22 |
| 9 | 1993 | 21 | |
| 10 | 1996 | 11 | |
| 11 | The role of platinum uptake and glutathione levels in L1210 cells sensitive and resistant to cisplatin, tetraplatin or carboplatin. | 1992 | 10 |
| 12 | Aspects of the biochemical pharmacology of cytembena. | 1975 | 8 |
| 13 | Methotrexate with thymidine, inosine, and allopurinol rescue: a phase I clinical study. | 1981 | 7 |
| 14 | 1993 | 5 | |
| 15 | Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) | 1987 | 5 |
| 16 | Toxicity and immunosuppressive activity of binary combinations of 2'-deoxycoformycin and 2'-deoxyadenosine. | 1981 | 3 |
| 17 | DIPYRIDAMOLE INDUCED-INHIBITION OF THYMIDINE INCORPORATION INVIVO AND POTENTIATION OF CB3717 CYTO-TOXICITY INVITRO | 1985 | 2 |
| 18 | The reaction of Cytembena with cellular thiol compounds. | 1976 | 2 |
| 19 | 2-AMINO-4-HYDROXY QUINAZOLINE ANALOGS OF FOLIC-ACID AS THYMIDYLATE SYNTHETASE INHIBITORS | 1979 | 1 |
| 20 | REPORT ON THE PHASE I TRIAL OF N-2, N-4, N-6-TRIHYDROXYMETHYL-N-2, N-4, N-6-TRIMETHYLMELAMINE (TRIMELAMOL) | 1985 | 1 |
About KR Harrap
KR Harrap is a scholar working on Oncology, Molecular Biology, Organic Chemistry, Pathology and Forensic Medicine and Genetics, having authored 21 papers that have together received 602 indexed citations. Recurring topics across this work include Metal complexes synthesis and properties (6 papers), Colorectal Cancer Treatments and Studies (3 papers), Cancer Treatment and Pharmacology (3 papers), Chemotherapy-induced organ toxicity mitigation (3 papers), Drug Transport and Resistance Mechanisms (3 papers), Acute Lymphoblastic Leukemia research (2 papers), Pharmaceutical studies and practices (2 papers) and Chemotherapy-related skin toxicity (2 papers). The work is most often cited by research in Oncology (355 citations), Pathology and Forensic Medicine (127 citations), Biochemistry (34 citations), Hematology (41 citations) and Molecular Biology (252 citations). KR Harrap has collaborated with scholars based in United Kingdom and United States. Frequent co-authors include Prakash Mistry, G Abel, LR Kelland, AH Calvert, DR Newell, Mark J. McKeage, Newell, J Siracký, Mark Jones and A.L. Jackman. Their work appears in journals such as British Journal of Cancer, British Journal of Clinical Pharmacology, International Journal of Oncology, Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.